Chemtatva Chiral Solutions (CCS) Private Limited
Chemtatva Chiral Solutions (CCS) is a Hyderabad-based CRDMO founded in 2021 that provides custom synthesis and specialty chemical products — including deuterium compounds, peptides, carbohydrates, nucleosides, chiral ligands, and organometallics — to pharmaceutical, biotech, OLED, and academic customers globally from a 48,000 sq ft GMP-compliant facility.
- Company typePrivate
- Founded2021
- HeadquartersHyderabad, India
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Chemtatva Chiral Solutions (CCS) Private Limited does
Chemtatva Chiral Solutions (CCS) Private Limited is a Hyderabad, India-based CRDMO (Contract Research, Development & Manufacturing Organization) founded in 2021 that delivers specialty synthetic chemistry products and custom synthesis services to pharmaceutical, biotechnology, OLED/electronics, and academic research customers across the USA, EU, and APAC. The company operates from a 48,000 sq ft GMP-compliant facility with ISO 9001:2015, ISO 14001:2015, and ISO 45001 certifications, four R&D labs, 28 fume hoods, dedicated peptide and glove-box labs, and two pilot plants providing 5,000L combined reactor capacity. It is led by founder-CEO Vishal Rajput, PhD, who brings prior senior leadership experience at Merck, Syngene International, and TCG Life-sciences (VP-Global head of CDMO Business).
CCS's product and capability stack spans eight core lines — deuterium compounds, amino acids and peptides (via solid-phase peptide synthesis / SPPS), carbohydrates, chiral ligands and catalysts, nucleosides and nucleotides, organometallics, OLED/electronics materials, and general reagents — supported by high-pressure (200 bar) and high-temperature (450°C) reactors, 300 ml/min preparative HPLC, and proprietary D-amino acid synthesis technology with a dedicated Deuterium Center of Excellence. The company reports 300+ products synthesized, 100+ deuterium SKUs, and 55+ global customers across 30+ countries, and has supplied regulatory starting materials for clinical Phase III molecules. In October 2025, CCS signed an MoU with Cambridge Isotope Laboratories, Inc. (CIL, an Otsuka Pharmaceutical subsidiary) to form Cambridge Isotope Laboratories, Pvt. Ltd., a Hyderabad-based JV with a new Genome Valley manufacturing facility planned for 2026, expanding CIL's deuterated reagent footprint in Asia while preserving the CCS legacy business.
The business model combines project-based custom synthesis (quote-based RFQ engagement, multi-year contracts) with catalog product sales (milligram to kilogram scale). Distribution is direct sales with global shipping coverage across North America, Europe, and Asia-Pacific, including dangerous-goods handling. Marketing is B2B and content-led through the corporate website, LinkedIn, technical articles, and whitepapers. The company is privately held and founder-led, with no disclosed institutional investors, venture capital, or private equity backing.
Chemtatva Chiral Solutions (CCS) Private Limited firmographics
Firmographics- Name
- Chemtatva Chiral Solutions (CCS) Private Limited
- Legal name
- Chemtatva Chiral Solutions Pvt. Ltd.
- Website
- https://chemtatva.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Chemtatva Chiral Solutions (CCS) is a Hyderabad-based CRDMO founded in 2021 that provides custom synthesis and specialty chemical products — including deuterium compounds, peptides, carbohydrates, nucleosides, chiral ligands, and organometallics — to pharmaceutical, biotech, OLED, and academic customers globally from a 48,000 sq ft GMP-compliant facility.
- Ownership category
- akta.pro rank
Chemtatva Chiral Solutions (CCS) Private Limited industry classification
Industry- Product category
- Custom Chemical Synthesis (CRDMO Services)
- NAICS
- Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
- akta.pro secondary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Chemtatva Chiral Solutions (CCS) Private Limited is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Chemtatva Chiral Solutions (CCS) Private Limited business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Custom Synthesis Services: CRDMO services providing custom synthesis, process R&D, and scale-up from grams to multi-MT commercial manufacturing for pharmaceutical and specialty chemical applications.
- Catalog Products: Sale of catalog chemical products including deuterium compounds, amino acids, peptides, carbohydrates, nucleosides, chiral ligands, organometallics, and reagents from milligram to kilogram scale.
- Regulatory Starting Materials: Supply of regulatory starting materials and key intermediates for clinical Phase III molecules, providing API and intermediate supply for pharmaceutical manufacturers.
- Analytical & Quality Services: Comprehensive testing, validation, and compliance support including CoA, NMR/GC/HPLC/LC-MS data, residual solvent reports, trace-metal reports, and stability documentation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Synthesis - Project-based pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Chemtatva Chiral Solutions (CCS) Private Limited product offering
Product offeringCore offering
Chemtatva Chiral Solutions (CCS) is a Contract Research, Development & Manufacturing Organization (CRDMO) that provides custom synthesis of complex organic molecules, deuterated compounds, peptides, and chiral intermediates for pharmaceutical, biotechnology, OLED, and academic research customers. Services span milligram-scale discovery support through kilo-lab and pilot-scale manufacturing, supported by analytical characterization and process development.
Product overview
Chemitatva Chiral Solutions (CCS) operates as a CRDMO (Contract Research, Development & Manufacturing Organization) offering a unified portfolio of specialty chemical products and services. The core portfolio consists of eight product lines: Deuterium Chemistry (NMR solvents, reagents, and deuterated building blocks), Amino Acids & Peptides (via SPPS), Carbohydrates, Chiral Ligands & Catalysts, Nucleosides & Nucleotides, Organometallics, and Reagents—all complemented by Custom Synthesis Services for tailored molecule development. Additional service verticals cover OLED & Electronics Materials and Pharmaceutical & Biotech Intermediates. These products share underlying synthetic chemistry capabilities (air/moisture-sensitive handling, high-pressure/high-temperature reactions, glycosylation, chiral catalysis) and are delivered from a unified GMP-compliant 48,000 sq ft facility in Hyderabad, enabling scale-up from lab (milligrams) to commercial (multi-metric ton) production.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom Synthesis Custom synthesis of novel and complex organic molecules for pharmaceutical, biotech, OLED, and specialty chemical customers, from milligram discovery scale through kilo-lab and pilot scale.
- Deuterium Chemistry / Deuterated Compounds Synthesis of deuterated compounds and stable isotope-labeled molecules used as internal standards, reference standards, and labeled API intermediates for pharmaceutical R&D and analytical applications.
- Peptide Synthesis Solid Phase Peptide Synthesis (SPPS) and solution-phase peptide synthesis services for therapeutic peptide R&D, including custom and catalog peptides at various scales and purity grades.
- Process Development and Scale-up Optimization of synthetic routes and scale-up from laboratory to kilo-lab and pilot scale for active pharmaceutical ingredients, intermediates, and specialty chemicals.
- Chiral Resolution and Chiral Intermediates Synthesis and resolution of chiral compounds and supply of chiral intermediates for asymmetric synthesis applications in pharmaceuticals and specialty chemicals.
- Reference Standards and Impurity Synthesis Custom synthesis of analytical reference standards, process-related impurities, and metabolite standards for pharmaceutical quality control, method validation, and regulatory submissions.
- Contract Research Fee-for-service custom research projects for pharmaceutical, biotech, and academic clients covering bespoke synthetic chemistry problems and feasibility studies.
Quantifiable outcome
- 300+ products synthesized for clinical and research applications
- +4 more outcomes
Companies that use Chemtatva Chiral Solutions (CCS) Private Limited
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Chemtatva Chiral Solutions (CCS) Private Limited technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Chemtatva Chiral Solutions (CCS) Private Limited partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cambridge Isotope Laboratories, Inc. (CIL)flagshipMoU signed to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This joint venture will expand CIL's global footprint in deuterated reagents and isotopically enriched products. Operations to begin at existing CCS facilities with new facility groundbreaking in 2026 at Genome Valley. CCS CEO Vishal Rajput will serve as general manager of the new entity.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Chemtatva Chiral Solutions (CCS) Private Limited competitors and assessment
Company assessmentBroad incumbents
- Cambrex: Global CDMO specializing in small-molecule API manufacturing and custom synthesis. Direct competitor for CCS's custom synthesis and complex-chemistry work, particularly for late-stage and commercial programs.
- Syngene International: Largest India-listed CRDMO, offering custom synthesis, biologics, and integrated discovery-to-manufacturing services. Highly comparable business model to CCS but at substantially greater scale and broader modality coverage, including the very company where CCS's CEO previously held senior leadership.
- Pharmaron: Global CRDMO with significant India operations (Hyderabad) offering custom synthesis, DMPK, biologics, and API manufacturing. Competes with CCS in custom synthesis and complex chemistry from a much larger, geographically diversified footprint.
Direct peers
- Combi-Blocks: Catalog supplier of specialty building blocks, including chiral compounds, heterocycles, and deuterated products. Directly comparable to CCS's catalog business across deuterium, chiral ligands, and organometallic reagent lines.
- Piramal Pharma Solutions: India-based CDMO offering custom synthesis, API manufacturing, and peptide capabilities globally. Overlaps directly with CCS's CRDMO model, including peptide and complex-chemistry offerings, though at materially larger scale.
- Cayman Chemical: Specialty chemistry supplier of catalog research chemicals, lipids, carbohydrates, and biochemical reagents. Comparable to CCS in catalog reach across niche chemistries (carbohydrates, nucleosides, labeled compounds) serving academic and industrial research customers.
- Aragen Life Sciences: India-headquartered CRDMO (formerly GVK Biosciences) providing custom synthesis, medicinal chemistry, and process development for pharma/biotech. Closely comparable to CCS on service portfolio, customer mix, and India CRDMO business model.
- AGC Chemicals (AGC Inc.): Specialty chemicals and CDMO division of AGC with strong fluorine, deuterium, and high-purity materials expertise. Highly comparable to CCS's deuterium chemistry, OLED materials, and complex organometallic capabilities, particularly the JV-adjacent relationship through CIL's parent network.
- Sai Life Sciences: India-based CRDMO offering custom synthesis, process R&D, and API manufacturing for global pharma and biotech. Directly comparable to CCS in chemistry expertise, India cost-arbitrage positioning, and India-based GMP capacity, though at a larger scale.
Emerging players
- Codexis: Specialty enzyme and chiral catalyst company serving pharma and fine chemicals customers. Adjacent competitor to CCS in chiral ligands and asymmetric catalysis, though with a differentiated enzyme-based technology platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Chemtatva Chiral Solutions (CCS) Private Limited social profiles
Digital presenceChemtatva Chiral Solutions (CCS) Private Limited compliance and trust
Trust signalCompliance4 records
Chemtatva Chiral Solutions (CCS) Private Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chemtatva Chiral Solutions (CCS) Private Limited leadership team
Management profileNumber of profiles
Profiles1 record
Chemtatva Chiral Solutions (CCS) Private Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chemtatva Chiral Solutions (CCS) Private Limited M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chemtatva Chiral Solutions (CCS) Private Limited
What does Chemtatva Chiral Solutions (CCS) Private Limited do?
Chemtatva Chiral Solutions (CCS) is a Contract Research, Development & Manufacturing Organization (CRDMO) that provides custom synthesis of complex organic molecules, deuterated compounds, peptides, and chiral intermediates for pharmaceutical, biotechnology, OLED, and academic research customers. Services span milligram-scale discovery support through kilo-lab and pilot-scale manufacturing, supported by analytical characterization and process development.
Is Chemtatva Chiral Solutions (CCS) Private Limited a public or private company?
Chemtatva Chiral Solutions (CCS) Private Limited is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Chemtatva Chiral Solutions (CCS) Private Limited founded?
Chemtatva Chiral Solutions (CCS) Private Limited was founded in 2021. It employs 11 to 50 people.
Where is Chemtatva Chiral Solutions (CCS) Private Limited based?
Chemtatva Chiral Solutions (CCS) Private Limited is headquartered in Hyderabad, India, in the Asia region.
How does Chemtatva Chiral Solutions (CCS) Private Limited make money?
Four revenue lines are on record. Custom Synthesis Services are the primary driver. The others are catalog Products, regulatory Starting Materials and analytical & Quality Services.
Who are Chemtatva Chiral Solutions (CCS) Private Limited's main competitors?
Broad incumbents on record are Cambrex, Syngene International and Pharmaron. Direct peers are Combi-Blocks, Piramal Pharma Solutions, Cayman Chemical, Aragen Life Sciences, AGC Chemicals (AGC Inc.) and Sai Life Sciences. Codexis is listed as an emerging player.
Does Chemtatva Chiral Solutions (CCS) Private Limited have an API?
No public API is recorded for Chemtatva Chiral Solutions (CCS) Private Limited.
What industry is Chemtatva Chiral Solutions (CCS) Private Limited in?
Chemtatva Chiral Solutions (CCS) Private Limited's product category is Custom Chemical Synthesis (CRDMO Services). Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 5417 and its SIC code is 8731.